Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer

NCT02263495 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Paclitaxel
DRUG: Eribulin
DRUG: Gemcitabine

Sponsor

Asan Medical Center

Collaborators

[object Object]
[object Object]
[object Object]